SynRG Brings its Business to the U.S.
The company hopes that in the current situation Russia will be even more attractive in terms of clinical trials for American small and mid-sized sponsors.
“We have always emphasized that one of the strategic goals set by SynRG is enhancing of research and investment attractiveness of Russia for foreign sponsors, so business development in the USA is a natural step along this strategic line," says SynRG CEO Igor Stefanov. “We spent quite some time interviewing candidates and conversing with the finalists, and now I am happy to introduce our new Director of Business Development, Anna Ravdel."
Anna Ravdel has graduated from the University of Manchester with an MBA degree, and worked as a marketing and sales director in various international companies. Prior to joining SynRG, Anna had worked as a Director of Business Development at Evidence Clinical and Pharmaceutical Research (Russia/USA) and at a global CRO Worldwide Clinical Trials.
SynRG also has plans of opening a Ukrainian office and, probably, a virtual office in Prague, as more and more of their clients are interested in the presence from Eastern European countries to Kazakhstan on a regional level.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025